Vaxart Secures $25M Lifeline for Its Oral Vaccine Quest

SOUTH SAN FRANCISCO, Calif. – April 17, 2026 – Vaxart, Inc. (OTCQX: VXRT), a biotechnology company pioneering needle-free, pill-based vaccines, announced today it has secured a flexible financing agreement for up to $25 million. The deal with Lincoln Park Capital Fund, a Chicago-based institutional investor, provides Vaxart with a critical financial tool as it advances its ambitious pipeline of oral vaccines for diseases including COVID-19 and norovirus.

The share purchase agreement gives Vaxart the right, but not the obligation, to sell shares of its common stock to Lincoln Park over a 24-month period. This arrangement provides the company with a controlled, on-demand source of capital to fund its operations and push its innovative candidates through costly clinical trials.

A Flexible Financial Tool

Unlike traditional equity raises that involve a single, large issuance of stock that can immediately dilute existing shareholders, this agreement is structured for flexibility. Vaxart maintains sole discretion over the timing and amount of any sales, allowing it to tap into the facility as needed based on market conditions and its own capital requirements.

Under the terms, Lincoln Park is obligated to purchase shares at prevailing market prices at the time of sale. The agreement notably includes no warrants or other complex financial instruments that often accompany such deals, and it contains no upper price limit on the shares Lincoln Park may purchase. Furthermore, Lincoln Park has agreed not to engage in any short selling or hedging of Vaxart's stock, a clause designed to align its interests with those of long-term shareholders.

"This agreement with Lincoln Park Capital provides flexible and efficient access to capital as we continue to pursue strategic partnerships, grants and other funding options to advance our oral vaccine programs,” said Jeroen Grasman, Chief Financial Officer of Vaxart, in the company's press release. “This facility allows us the sole discretion to strengthen our balance sheet on an as-needed basis as we continue to execute on our clinical milestones while remaining focused on driving long-term value for our shareholders."

As consideration for entering the agreement, Vaxart issued 447,067 shares to Lincoln Park. Before any sales can commence, a registration statement must be declared effective by the U.S. Securities and Exchange Commission (SEC).

The Lincoln Park Playbook

The financing partner, Lincoln Park Capital, is a familiar name in the biotech and emerging growth sectors. The firm specializes in these types of equity line facilities, providing a recurring source of capital for public companies navigating the long and expensive road of product development. This investment model offers an alternative to more disruptive financing methods, allowing companies to draw funds incrementally.

Lincoln Park has a significant track record of similar agreements with other clinical-stage companies. In the past few years, firms like Plus Therapeutics, Cingulate, and Daré Bioscience have all entered into multi-million dollar purchase agreements with the investor. This pattern establishes Lincoln Park as a strategic financial partner in the life sciences ecosystem, providing a predictable funding mechanism that gives development-stage companies a degree of financial certainty without forcing them to raise large sums when market conditions may be unfavorable.

For Vaxart, partnering with a firm experienced in this specific financing structure provides a well-trodden path to bolstering its balance sheet. It signals a move to utilize established financial tools to manage the inherent volatility and high cash burn rate of biotechnology research and development.

Balancing the Books: Strategy or Necessity?

While any stock issuance carries the potential for dilution, Vaxart’s move appears to be a calculated, strategic effort to extend its financial runway ahead of a crisis. The company's most recent financial disclosures indicated a cash runway extending into the first quarter of 2026. With significant research and development expenses—which climbed to $30.7 million in the first quarter of 2025—the need for additional, non-dilutive, or strategically managed dilutive funding is a constant reality.

This financing agreement comes on the heels of several major financial and strategic successes for Vaxart. The company is executing on a contract from the Biomedical Advanced Research and Development Authority (BARDA) worth up to $460.7 million to fund a large-scale Phase 2b trial for its oral COVID-19 vaccine. It has also secured a global partnership with Dynavax, which included a $25 million upfront payment and a $5 million equity investment.

These significant injections of non-dilutive and partnership-related capital have transformed Vaxart’s financial position over the past two years. However, the high costs of late-stage clinical trials mean that even with substantial government support, a company of Vaxart's size must continuously plan for its future capital needs. This $25 million facility acts as a financial backstop, providing a bridge to future milestones or partnerships. Market reaction has been muted, with the stock showing a modest gain, suggesting investors may view the arrangement as a pragmatic step rather than a red flag. Analyst sentiment remains broadly bullish, with price targets suggesting significant upside, contingent on the company successfully executing on its clinical programs.

Fueling the Pill Vaccine Revolution

The ultimate purpose of this capital is to propel Vaxart’s unique technology toward commercialization. The company is at the forefront of developing oral recombinant vaccines, which are administered as pills and can be stored at room temperature. This platform has the potential to revolutionize vaccine distribution and administration, eliminating the need for cold-chain logistics and trained medical personnel for injections.

The most prominent program is its oral COVID-19 vaccine candidate, currently in a 10,000-participant Phase 2b trial funded by BARDA's Project NextGen. The trial is comparing Vaxart’s pill directly against an FDA-approved mRNA booster, with topline data anticipated in late 2026. A successful outcome could position Vaxart as a key player in the future of COVID-19 protection, particularly if its vaccine demonstrates superior mucosal immunity, which could be more effective at blocking transmission.

Beyond COVID-19, Vaxart is advancing a bivalent oral vaccine for norovirus, the highly contagious stomach flu for which no vaccine currently exists. Following positive data in elderly and lactating populations, a new Phase 1 trial is underway, with data expected as early as mid-2025. Success in this program could open a massive market and address a significant public health need. The new funding will be instrumental in supporting these parallel programs, ensuring Vaxart can continue to hit critical development milestones on its path to potentially changing the way the world is vaccinated.